Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models
Sandra Feijóo‐Bandín, Alana Aragón‐Herrera, Manuel Otero-Santiago, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5634-5634
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Low-grade inflammation in type 2 diabetes: a cross-sectional study from a Danish diabetes outpatient clinic
Tina Okdahl, Anne‐Marie Wegeberg, Flemming Pociot, et al.
BMJ Open (2022) Vol. 12, Iss. 12, pp. e062188-e062188
Open Access | Times Cited: 47
SGLT-2 Inhibitors and the Inflammasome: What’s Next in the 21st Century?
Dimitris Kounatidis, Natalia G. Vallianou, Angelos Evangelopoulos, et al.
Nutrients (2023) Vol. 15, Iss. 10, pp. 2294-2294
Open Access | Times Cited: 23
View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences
Guglielmina Froldi
Pharmaceuticals (2024) Vol. 17, Iss. 4, pp. 478-478
Open Access | Times Cited: 15
The alleviative effects of canagliflozin on imiquimod-induced mouse model of psoriasis-like inflammation
H. Salman, Adeeb A. Al-Zubaidy, Alaa Hamza Abbas, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024)
Closed Access | Times Cited: 13
Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages
Elena Y. Rykova, Vadim V. Klimontov, Elena Kazakova, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1670-1670
Open Access | Times Cited: 1
The anti-inflammatory and immunological properties of SGLT-2 inhibitors
Giulia Bendotti, Laura Montefusco, Ida Pastore, et al.
Journal of Endocrinological Investigation (2023) Vol. 46, Iss. 12, pp. 2445-2452
Closed Access | Times Cited: 20
The Role of Inflammasomes in Heart Failure
Panayotis K. Vlachakis, Panagiotis Theofilis, Ioannis Kachrimanidis, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5372-5372
Open Access | Times Cited: 6
An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis
Dóra Balogh, László Wagner, Andrea Fekete
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 7789-7789
Open Access | Times Cited: 15
Dapagliflozin/Hesperidin Combination Mitigates Lipopolysaccharide-Induced Alzheimer’s Disease in Rats
Maaly A. Abd Elmaaboud, Remon S. Estfanous, Aliaa Atef, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 10, pp. 1370-1370
Open Access | Times Cited: 13
The current landscape for diabetes treatment: Preventing diabetes-associated CV risk
Angela Dardano, Cristina Bianchi, Monia Garofolo, et al.
Atherosclerosis (2024) Vol. 394, pp. 117560-117560
Closed Access | Times Cited: 5
The SGLT2 inhibitor remogliflozin induces vasodilation in the femoral artery of rabbits via activation of a Kv channel, the SERCA pump, and the cGMP signaling pathway
Minju Park, Wenwen Zhuang, Junsu Jeong, et al.
Toxicology and Applied Pharmacology (2025) Vol. 495, pp. 117228-117228
Closed Access
Targeting Diabetic Atherosclerosis: The Role of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Nonsteroidal Mineralocorticoid Receptor Antagonists in Vascular Protection and Disease Modulation
Merita Rroji, Nereida Spahia, Andreja Figurek, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 728-728
Open Access
Emerging horizons: clinical applications and multifaceted benefits of SGLT-2 inhibitors beyond diabetes
Qing Feng, Moya Wu, Zizhao Mai
Frontiers in Cardiovascular Medicine (2025) Vol. 12
Open Access
The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats
Alana Aragón‐Herrera, Sandra Moraña‐Fernández, Manuel Otero-Santiago, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 161, pp. 114535-114535
Open Access | Times Cited: 10
Mouse Models with SGLT2 Mutations: Toward Understanding the Role of SGLT2 beyond Glucose Reabsorption
Keiko Unno, Kyoko Taguchi, Yoshiichi Takagi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6278-6278
Open Access | Times Cited: 10
SGLT -2 Inhibitors and the Inflammasome: What's next in the 21st century?
Dimitris Kounatidis, Natalia G. Vallianou, Angelos Evangelopoulos, et al.
(2023)
Open Access | Times Cited: 10
Sodium–Glucose Cotransporter Protein 2 Inhibitors: Novel Application for the Treatment of Obesity-Associated Hypertension
Yilan Hu, Jiaqi Bao, Zhicheng Gao, et al.
Diabetes Metabolic Syndrome and Obesity (2024) Vol. Volume 17, pp. 407-415
Open Access | Times Cited: 3
Identification of key genes increasing susceptibility to atrial fibrillation in nonalcoholic fatty liver disease and the potential mechanisms: mitochondrial dysfunction and systemic inflammation
Baiyin Zhong, Zhonghui Xie, Jianhong Zhang, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Impact of Dapagliflozin on Atherosclerosis through Inflammation and Oxidative Pathways
Zainab Abdlkadhim Aboshnin, Safa Azhar Razzaq, Zahraa Ibraheim, et al.
Journal of Angiotherapy (2024) Vol. 8, Iss. 2
Open Access | Times Cited: 2
The Off-Target Cardioprotective Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors: An Overview
Loredana N. Ionică, Adina V. Lința, Alina D. Bătrîn, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7711-7711
Open Access | Times Cited: 2
Kidneys in heart failure: Impact of flozins
Tomasz Stompór, Agata Winiarska
Kardiologia Polska (2023) Vol. 81, Iss. 11, pp. 1071-1080
Open Access | Times Cited: 6
Sotagliflozin attenuates cardiac dysfunction and remodeling in myocardial infarction rats
Peng Zhong, Jingjing Zhang, Yanzhao Wei, et al.
Heliyon (2023) Vol. 9, Iss. 11, pp. e22423-e22423
Open Access | Times Cited: 6
Gliflozins Have an Anti-Inflammatory Effect on Renal Proximal Tubular Epithelial Cells in a Diabetic and Inflammatory Microenvironment In Vitro
Benjamin Koch, Dominik C. Fuhrmann, Ralf Schubert, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 1811-1811
Open Access | Times Cited: 5
Risk of ICU Admission and Related Mortality in Patients With Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors: A Territory-Wide Retrospective Cohort Study
Pauline Yeung Ng, Andrew Kei‐Yan Ng, April Ip, et al.
Critical Care Medicine (2023) Vol. 51, Iss. 8, pp. 1074-1085
Open Access | Times Cited: 4
The determination of the comparative effect of Ertugliflozin, Pioglitazone, and Metformin on patients of non-alcoholic fatty liver disease in type 2 diabetes mellitus.
Adil Khaliq, Haroon Badshah, Yasar Shah, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top